The Long-Term Survival of a Patient With Stage IV Renal Cell Carcinoma Following an Integrative Treatment Approach Including the Intravenous α-Lipoic Acid/Low-Dose Naltrexone Protocol
In this case report, we describe the treatment of a 64-year-old male patient diagnosed with metastatic renal cell carcinoma (RCC) in June of 2008. In spite of a left nephrectomy and the standard oncological protocols, the patient developed a solitary left lung metastasis that continued to grow. He was informed that given his diagnosis and poor response to conventional therapy, any further treatment would, at best, be palliative. The patient arrived at the Integrative Medical Center of New Mexico in August of 2010. He was in very poor health, weak, and cachectic. An integrative program—developed by one of the authors using intravenous (IV) α-lipoic acid, IV vitamin C, low-dose naltrexone, and hydroxycitrate, and a healthy life style program—was initiated. From August 2010 to August 2015, the patient’s RCC with left lung metastasis was followed closely using computed tomography and positron emission tomography/computed tomography imaging. His most recent positron emission tomography scan demonstrated no residual increased glucose uptake in his left lung. After only a few treatments of IV α-lipoic acid and IV vitamin C, his symptoms began to improve, and the patient regained his baseline weight. His energy and outlook improved, and he returned to work. The patient had stable disease with disappearance of the signs and symptoms of stage IV RCC, a full 9 years following diagnosis, with a gentle integrative program, which is essentially free of side effects. As of November 2017 the patient feels well and is working at his full-time job.
I am sorry to hear about your husband. Is he planning to do conventional treatments such as chemo or he only accepts alternative treatments?
Please note that on this website the contributors and myself discussed many treatment options that offer evidence-based hope even when the conventional treatment approaches stop working.
Some can be used as stand alone, others can be used together with the conventional treatments to help increase or enable the effectiveness of conventional treatments. Because of the angle we take here to look at cancer (e.g. cell metabolism, hormone modulation, ion dynamics modulation, etc.) most of the treatments discussed here are relevant for most of the cancers, including kidney cancer. Please take the time to read some posts on this website. Even if a post was written 3-years ago it will have the same relevance as if it was written today.
Yes, dewarmers can also be relevant and I would certainly try them.
One that I would consider is Mebendazole https://www.cancertreatmentsresearch.com/the-over-the-counter-drug-mebendazole-acts-like-chemotherapy-but-with-virtually-no-side-effects/
The other is Fenbendazole https://www.cancertreatmentsresearch.com/fenbendazole/
Angiogenesis inhibitors are specifically relevant for kidney cancer as well as peritoneal mets. Here is a list of angiogenesis inhibitors https://www.cancertreatmentsresearch.com/category/angiogenesis-inhibitors/
He never does Chemo or Radiation. To this point even Conventional Treatment cant effective for him. He is going to do Poly MPV IV. I will check on those website. Thank you.
Dr. Khan at Medicore in Canada said they used DCA successfully in renal cell cancer https://medicorcancer.com/new-dca-publication-world-first/
I discussed DCA here https://www.cancertreatmentsresearch.com/dichloroacetate-dca-treatment-strategy/
I would not loose the time with one treatment only.